| Donna Marchisotto, RN, MSN,PMHCNS | |
|
2311 83rd St, Brooklyn, NY 11214-2715 | |
| (347) 586-8183 | |
| Not Available |
| Full Name | Donna Marchisotto |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Psychiatric/mental Health, Adult |
| Location | 2311 83rd St, Brooklyn, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265054530 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SP0809X | Clinical Nurse Specialist - Psychiatric/mental Health, Adult | 325399 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Donna Marchisotto, RN, MSN,PMHCNS 2311 83rd St, Brooklyn, NY 11214-2715 Ph: (347) 586-8183 | Donna Marchisotto, RN, MSN,PMHCNS 2311 83rd St, Brooklyn, NY 11214-2715 Ph: (347) 586-8183 |
News Archive
Large and rare chromosomal copy number variants are uncommon in patients with bipolar disorder, even those with early-onset disease, study findings confirm.
Research by the University of Southampton and University Hospital Southampton has demonstrated that a newly-developed respirator hood is a safe form of personal protective equipment (PPE) for frontline healthcare workers and support staff.
Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.
MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug-development company, announces receipt of notice from the U.S. Food and Drug Administration authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer.
In years to come, our personal memories of the COVID-19 pandemic are likely to be etched in our minds with precision and clarity, distinct from other memories of 2020.
› Verified 1 days ago
Mrs. Mayya K Gitelman, NURSE PRACTITIONER Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 3101 Ocean Pkwy, Brooklyn, NY 11235 Phone: 718-946-2481 Fax: 718-266-5346 | |
Alexandra Giralt Hughes, CNS Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 299 Henry St Apt 2a, Brooklyn, NY 11201 Phone: 407-227-9518 | |
Helene Thousand, RN Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 175 Remsen St, Brooklyn, NY 11201 Phone: 718-852-5558 Fax: 718-852-5666 | |
Eun Hye Kim, Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 16 Sumner Pl, Brooklyn, NY 11206 Phone: 718-336-9500 Fax: 718-336-9505 | |
Mrs. Verna Fleary-alexis, FNP Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 379 Lincoln Rd, Brooklyn, NY 11225 Phone: 718-953-0422 Fax: 718-953-0422 | |
Kit So, ANP Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 970 41st St Apt 6h, Brooklyn, NY 11219 Phone: 917-815-8628 |